Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FENC Adherex Technologies	$8.66 +6.0%	$8.42	$3.96 ▼ $9.42	$227.24M	0.4	58,881 shs	166,030 shs
GNFT GENFIT	$4.32 +4.8%	$3.90	$2.55 ▼ $6.42	$206.01M	1.14	3,812 shs	1,582 shs
ICCC ImmuCell	$6.09 +1.8%	$6.50	$3.34 ▼ $7.60	$54.09M	0.3	11,066 shs	4,414 shs
PRQR ProQR Therapeutics	$2.26 +2.3%	$2.13	$1.07 ▼ $4.62	$232.52M	0.43	274,267 shs	460,691 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FENC Adherex Technologies	+6.00%	+3.59%	-0.80%	+10.04%	+53.82%
GNFT GENFIT	+1.58%	+8.17%	+8.83%	+2.03%	-1.95%
ICCC ImmuCell	+1.84%	-0.16%	-12.37%	-6.60%	+65.49%
PRQR ProQR Therapeutics	+2.26%	+10.24%	+4.15%	+35.33%	+7.62%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership
FENC Adherex Technologies	1.8456 of 5 stars	3.5	1.0	1.7	2.5
GNFT GENFIT	2.186 of 5 stars	3.5	3.0	3.3	0.0
ICCC ImmuCell	0.7913 of 5 stars	0.0	5.0	2.7	0.0
PRQR ProQR Therapeutics	2.6997 of 5 stars	3.6	5.0	2.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FENC Adherex Technologies	3.00	Buy	$13.33	53.96% Upside
GNFT GENFIT	3.00	Buy	$9.00	108.53% Upside
ICCC ImmuCell	0.00	N/A	N/A	N/A
PRQR ProQR Therapeutics	3.13	Buy	$8.00	253.98% Upside

Current Analyst Ratings Breakdown

Latest ICCC, GNFT, FENC, and PRQR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	FENC Adherex Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
8/19/2025	GNFT GENFIT	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00
8/15/2025	FENC Adherex Technologies	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/15/2025	FENC Adherex Technologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $14.00
8/8/2025	PRQR ProQR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
7/11/2025	PRQR ProQR Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/27/2025	PRQR ProQR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00
6/27/2025	PRQR ProQR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$8.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FENC Adherex Technologies	$47.54M	5.07	$0.03 per share	252.97	($0.27) per share	-32.07
GNFT GENFIT	$76.77M	2.81	$0.07 per share	58.90	$1.50 per share	2.88
ICCC ImmuCell	$26.49M	2.08	$0.07 per share	93.00	$3.30 per share	1.85
PRQR ProQR Therapeutics	$16.49M	14.42	N/A	N/A	$0.72 per share	3.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FENC Adherex Technologies	-$440K	-$0.42	N/A	N/A	N/A	-35.05%	N/A	-23.92%	11/6/2025 (Estimated)
GNFT GENFIT	$1.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
ICCC ImmuCell	-$2.16M	$0.19	32.05	∞	N/A	6.23%	6.25%	3.87%	N/A
PRQR ProQR Therapeutics	-$30.04M	-$0.46	N/A	N/A	N/A	-238.52%	-61.25%	-28.13%	11/6/2025 (Estimated)

Latest ICCC, GNFT, FENC, and PRQR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	FENC Adherex Technologies	-$0.06	-$0.11	-$0.05	-$0.11	$9.52 million	$9.76 million
8/14/2025	Q2 2025	ICCC ImmuCell	N/A	$0.06	N/A	$0.06	N/A	$6.45 million
8/7/2025	Q2 2025	PRQR ProQR Therapeutics	-$0.08	-$0.14	-$0.06	-$0.14	$5.01 million	$4.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FENC Adherex Technologies	N/A	N/A	N/A	N/A	N/A
GNFT GENFIT	N/A	N/A	N/A	N/A	N/A
ICCC ImmuCell	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FENC Adherex Technologies	N/A	4.85	4.97
GNFT GENFIT	0.08	1.23	1.23
ICCC ImmuCell	0.28	3.85	2.21
PRQR ProQR Therapeutics	N/A	3.76	3.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FENC Adherex Technologies	55.51%
GNFT GENFIT	2.24%
ICCC ImmuCell	13.47%
PRQR ProQR Therapeutics	32.65%

Insider Ownership

Company	Insider Ownership
FENC Adherex Technologies	11.76%
GNFT GENFIT	4.20%
ICCC ImmuCell	5.60%
PRQR ProQR Therapeutics	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FENC Adherex Technologies	10	27.81 million	24.54 million	Optionable
GNFT GENFIT	120	50.00 million	47.90 million	Not Optionable
ICCC ImmuCell	70	9.05 million	8.54 million	Not Optionable
PRQR ProQR Therapeutics	180	105.21 million	96.38 million	Optionable

ICCC, GNFT, FENC, and PRQR Headlines

Recent News About These Companies

ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of "Buy" by Brokerages

August 20 at 2:37 AM | marketbeat.com

ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Recommendation of "Buy" from Analysts

August 19, 2025 | americanbankingnews.com

PRQR | ProQR Therapeutics N.V. Stock Price & News - WSJ

August 12, 2025 | wsj.com

ProQR Therapeutics (NASDAQ:PRQR) Earns "Buy" Rating from Chardan Capital

August 9, 2025 | marketbeat.com

ProQR Therapeutics (NASDAQ:PRQR) Stock Price Passes Above 50-Day Moving Average - What's Next?

August 8, 2025 | marketbeat.com

ProQR Announces Second Quarter 2025 Operating and Financial Results

August 7, 2025 | globenewswire.com

ProQR Therapeutics (PRQR) Expected to Announce Earnings on Thursday

August 7, 2025 | marketbeat.com

Monaco Asset Management SAM Increases Holdings in ProQR Therapeutics N.V. (NASDAQ:PRQR)

July 30, 2025 | marketbeat.com

ProQR Announces Upcoming Presentation at RNA Editing Summit

July 28, 2025 | globenewswire.com

ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Rating of "Buy" by Brokerages

July 25, 2025 | marketbeat.com

ProQR Therapeutics price target raised to $5 from $4 at Evercore ISI

July 12, 2025 | msn.com

ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles - Investing.com

July 8, 2025 | investing.com

PRQR - ProQR Therapeutics NV Sustainability - Morningstar

July 3, 2025 | morningstar.comM

PRQR - ProQR Therapeutics NV Key Metrics - Morningstar

July 2, 2025 | morningstar.comM

ProQR Therapeutics NV (PRQR) Stock Forums - Investing.com

June 29, 2025 | investing.com

ProQR Therapeutics N.V. (PRQR) - Yahoo Finance

June 29, 2025 | finance.yahoo.com

ProQR Therapeutics N.V.: ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

June 27, 2025 | finanznachrichten.de

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

June 26, 2025 | globenewswire.com

ProQR Therapeutics Reports Q1 2025 Financial Results

June 2, 2025 | tipranks.com

ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces pivotal year

May 24, 2025 | investing.com

ProQR Therapeutics (PRQR) Price Target Lowered by Oppenheimer | PRQR Stock News

May 13, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ICCC, GNFT, FENC, and PRQR Company Descriptions

Adherex Technologies NASDAQ:FENC

$8.66 +0.49 (+6.00%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$8.66 0.00 (0.00%)

As of 08/22/2025 04:10 PM Eastern

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

GENFIT NASDAQ:GNFT

$4.32 +0.20 (+4.76%)

As of 08/22/2025 03:56 PM Eastern

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

ImmuCell NASDAQ:ICCC

$6.09 +0.11 (+1.84%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$6.05 -0.04 (-0.66%)

As of 08/22/2025 04:10 PM Eastern

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

ProQR Therapeutics NASDAQ:PRQR

$2.26 +0.05 (+2.26%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.34 +0.08 (+3.54%)

As of 08/22/2025 06:39 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time